TY - JOUR
T1 - High-yield identification of pathogenic NF1 variants by skin fibroblast transcriptome screening after apparently normal diagnostic DNA testing
AU - Douben, Hannie C.W.
AU - Nellist, Mark
AU - van Unen, Leontine
AU - Elfferich, Peter
AU - Kasteleijn, Esmee
AU - Hoogeveen-Westerveld, Marianne
AU - Louwen, Jesse
AU - van Veghel-Plandsoen, Monique
AU - de Valk, Walter
AU - Saris, Jasper J.
AU - Hendriks, Femke
AU - Korpershoek, Esther
AU - Hoefsloot, Lies H.
AU - van Vliet, Margreethe
AU - van Bever, Yolande
AU - van de Laar, Ingrid
AU - Aten, Emmelien
AU - Lachmeijer, Augusta M.A.
AU - Taal, Walter
AU - van den Bersselaar, Lisa
AU - Schuurmans, Juliette
AU - Oostenbrink, Rianne
AU - van Minkelen, Rick
AU - van Ierland, Yvette
AU - van Ham, Tjakko J.
N1 - Funding Information:
TvH was supported by an Erasmus University Rotterdam (EUR) fellowship.
Publisher Copyright:
© 2022 The Authors. Human Mutation published by Wiley Periodicals LLC.
PY - 2022/12
Y1 - 2022/12
N2 - Neurofibromatosis type 1 (NF1) is caused by inactivating mutations in NF1. Due to the size, complexity, and high mutation rate at the NF1 locus, the identification of causative variants can be challenging. To obtain a molecular diagnosis in 15 individuals meeting diagnostic criteria for NF1, we performed transcriptome analysis (RNA-seq) on RNA obtained from cultured skin fibroblasts. In each case, routine molecular DNA diagnostics had failed to identify a disease-causing variant in NF1. A pathogenic variant or abnormal mRNA splicing was identified in 13 cases: 6 deep intronic variants and 2 transposon insertions causing noncanonical splicing, 3 postzygotic changes, 1 branch point mutation and, in 1 case, abnormal splicing for which the responsible DNA change remains to be identified. These findings helped resolve the molecular findings for an additional 17 individuals in multiple families with NF1, demonstrating the utility of skin-fibroblast-based transcriptome analysis for molecular diagnostics. RNA-seq improves mutation detection in NF1 and provides a powerful complementary approach to DNA-based methods. Importantly, our approach is applicable to other genetic disorders, particularly those caused by a wide variety of variants in a limited number of genes and specifically for individuals in whom routine molecular DNA diagnostics did not identify the causative variant.
AB - Neurofibromatosis type 1 (NF1) is caused by inactivating mutations in NF1. Due to the size, complexity, and high mutation rate at the NF1 locus, the identification of causative variants can be challenging. To obtain a molecular diagnosis in 15 individuals meeting diagnostic criteria for NF1, we performed transcriptome analysis (RNA-seq) on RNA obtained from cultured skin fibroblasts. In each case, routine molecular DNA diagnostics had failed to identify a disease-causing variant in NF1. A pathogenic variant or abnormal mRNA splicing was identified in 13 cases: 6 deep intronic variants and 2 transposon insertions causing noncanonical splicing, 3 postzygotic changes, 1 branch point mutation and, in 1 case, abnormal splicing for which the responsible DNA change remains to be identified. These findings helped resolve the molecular findings for an additional 17 individuals in multiple families with NF1, demonstrating the utility of skin-fibroblast-based transcriptome analysis for molecular diagnostics. RNA-seq improves mutation detection in NF1 and provides a powerful complementary approach to DNA-based methods. Importantly, our approach is applicable to other genetic disorders, particularly those caused by a wide variety of variants in a limited number of genes and specifically for individuals in whom routine molecular DNA diagnostics did not identify the causative variant.
UR - http://www.scopus.com/inward/record.url?scp=85141604748&partnerID=8YFLogxK
U2 - 10.1002/humu.24487
DO - 10.1002/humu.24487
M3 - Article
C2 - 36251260
AN - SCOPUS:85141604748
SN - 1059-7794
VL - 43
SP - 2130
EP - 2140
JO - Human Mutation
JF - Human Mutation
IS - 12
ER -